Everyone tells you something different. Your friend says it is hormones. Your sister says it is muscle loss. Someone else says it is just aging metabolism. Which one is it?
Here is the honest answer: it is genuinely all of them, working together, in proportions that differ from woman to woman. This is exactly why menopause weight gain feels so confusing. The explanations you have heard are not necessarily wrong. They are just incomplete on their own.
You are not imagining that something has changed. And this is not a reflection of anything you have done wrong.
This article builds on our related overview of why weight changes during midlife by going deeper into each individual contributor. The goal is to help you understand the mechanism behind your own experience, rather than picking one explanation and assuming it is the whole story.
If this resonates, you deserve more than a generic answer. Learn more about personalized weight management at Her Vital Wellness.
Key takeaways
- Menopause weight gain results from multiple interacting factors, not any single cause.
- Estrogen decline primarily affects where fat is stored (shifting toward the abdomen), more than how much total weight is gained.
- Muscle loss reduces resting energy expenditure, meaning the same habits that once maintained your weight may no longer do so.
- Insulin sensitivity can shift during the menopausal transition, making weight management feel harder even without dietary changes.
- Sleep disruption and chronic stress independently contribute through appetite-regulating hormones and cortisol.
- Your metabolism is not “broken.” These are real, physiologically explainable changes, and several of them are genuinely modifiable.
—
What is happening?
Weight and body composition changes during menopause result from the interaction of several distinct physiological processes occurring around the same time, rather than a single cause.
Untangling these requires looking at each one somewhat separately, since they operate through genuinely different mechanisms, even though they often reinforce each other.
Research from the SWAN study (Study of Women’s Health Across the Nation) provides some of the strongest evidence on this topic. SWAN followed women for 18 years across the menopausal transition and found that approximately 2 years before the final menstrual period, the rate of fat gain doubled and lean mass declined. This continued until about 2 years after the final menstrual period, suggesting that accelerated gains in fat mass and losses of lean mass are menopause-related phenomena.
Here is what the evidence tells us about each contributor.
—
Factor one: estrogen and fat distribution
Estrogen influences where the body preferentially stores fat, and research suggests this effect may matter more for fat distribution than for total body weight itself.
Before menopause, fat is more commonly stored in the hips and thighs (sometimes called a “pear” pattern). As estrogen declines, fat storage often shifts toward the abdomen (an “apple” pattern), even without significant total weight change.
This shift matters clinically because abdominal fat, particularly visceral fat, is more metabolically active. It is associated with increased cardiovascular and metabolic risk compared to fat stored elsewhere.
A large meta-analysis of over 1 million women found that the change in fat mass quantity between premenopausal and postmenopausal women was attributable predominantly to increasing age. Menopause had no significant additional influence on total fat mass. However, the decrease in total leg fat percentage and increase in measures of central fat were indicative of a possible change in fat mass distribution after menopause.
It is worth being precise: this is a redistribution effect more clearly than it is a total-weight-gain effect. Estrogen decline alone does not fully explain why total body weight increases for many women during this transition. That requires looking at the additional factors below.
—
Factor two: aging and muscle loss (sarcopenia)
Independent of menopause specifically, muscle mass and strength naturally decline with age. This process can begin as early as the mid-30s and tends to accelerate around the menopause transition.
When this decline becomes more significant, it is sometimes referred to clinically as sarcopenia. One cross-sectional study of 144 women found that appendicular lean mass was significantly lower in late perimenopausal women compared to early perimenopausal women. The prevalence of sarcopenia jumped from 3% in early perimenopause to 30% in late perimenopause.
Because muscle tissue burns more energy at rest than fat tissue, a decline in muscle mass is associated with a corresponding decline in resting energy expenditure (the calories your body burns simply existing).This means the same eating and activity pattern that once maintained your weight may no longer do so. Not because of any change in willpower or effort, but because the underlying metabolic math has genuinely shifted.
This is arguably one of the more underappreciated contributors to midlife weight changes, and it is also one of the more directly modifiable ones. Resistance training directly addresses muscle loss, as explored in more depth in our related article on why strength training matters more after 40.
—
Factor three: insulin sensitivity and metabolic shifts
Research suggests insulin sensitivity may decrease during the menopause transition, independent of weight change.
When the body becomes somewhat less efficient at processing blood sugar, this shift is associated with increased fat storage, particularly in the abdominal area. One study found that postmenopausal women had a 28% lower insulin sensitivity index compared to premenopausal women, along with increased lipid deposition in the liver and skeletal muscle.
The American Heart Association’s scientific statement on menopause and cardiovascular risk noted that while menopause was not independently linked to increases in insulin or glucose beyond age, the prevalence of metabolic syndrome (and the clustering of its components) appeared to increase with menopause, beyond the effects of chronological aging.
This factor interacts closely with the fat redistribution effect described above, since visceral fat itself is associated with further reductions in insulin sensitivity, creating a self-reinforcing cycle for some women.
Weight management may feel more effortful even without a change in diet or activity level. This is not a personal failing. It is a physiological shift.
—
Factor four: sleep and stress
Sleep disruption, common during perimenopause due to hot flashes and night sweats, is associated with changes in hunger-regulating hormones.
Research shows that sleep restriction increases levels of ghrelin (a hormone that stimulates appetite) and may decrease levels of leptin (a hormone that signals fullness). A randomized study found that just 14 days of sleep restriction led to increased calorie intake (an average of 308 extra calories per day), significant weight gain, and notably, increased visceral fat deposition.
The American Heart Association’s scientific statement on sleep confirmed that chronic short sleep (6 hours or less) is correlated with elevated BMI and waist circumference, with short sleepers being as much as 1.7 kg/m² heavier than long sleepers.
Chronic stress, common during this demanding life stage, is associated with elevated cortisol. Research links chronic cortisol elevation to increased abdominal fat storage specifically. This means stress may compound the same fat-redistribution pattern already being driven by estrogen decline.
Addressing sleep and stress are often among the most impactful first steps, even before any other intervention.
—
Factor five: activity changes and nutrition patterns
Physical activity levels sometimes decline gradually with age due to busier schedules, joint discomfort, or simply less structured activity than in earlier decades. This compounds muscle loss and its metabolic consequences.
Nutrition patterns that worked well in earlier decades, particularly around protein intake, may need genuine recalibration given the anabolic resistance and metabolic shifts described above. This is not because of any failure in the approach itself, but because the underlying physiology has changed.
Research shows that postmenopausal women may demonstrate blunted anabolic responses to protein intake and exercise, meaning higher volumes of exercise and adequate protein distribution across meals may be needed to maintain muscle mass.
—
Factor six: medications and medical contributors
Certain medications can be associated with weight changes as a side effect. Conditions like thyroid dysfunction can independently contribute to weight changes that may be mistakenly attributed entirely to menopause.
This is part of why a broader evaluation, rather than assuming menopause explains everything, is worthwhile when weight changes are significant or unexpected.
—
Factor seven: genetics
Individual genetic variation influences body composition, fat distribution patterns, and metabolic response to hormonal changes. This is part of why two women with very similar lifestyles can experience quite different degrees of weight and body composition change during this same transition.
—
What does the evidence show?
Taken together, research supports that midlife weight and body composition changes are multifactorial.
Estrogen-related fat redistribution, age-related muscle loss, shifting insulin sensitivity, sleep disruption, and lifestyle factors all contribute simultaneously and interactively, rather than any single factor operating in isolation.
This is an important corrective to both oversimplified explanations you may have encountered: it is not simply “hormones,” and it is not simply “diet and exercise.” It is a genuine interaction of several distinct mechanisms.
It is also worth stating clearly what the evidence does not support: “your metabolism is broken” is not an accurate or useful way to describe what is happening. Metabolic changes during this transition are real, measurable, and explainable through the mechanisms above. They represent your body’s genuine, expected physiological response to a hormonal transition, not a malfunction, and importantly, they are not something to blame yourself for.
—
What every woman should know
– Menopause weight gain results from multiple, interacting factors. Estrogen-related fat redistribution, muscle loss, insulin sensitivity changes, sleep, stress, and lifestyle all play a role. Not any single cause.
– Estrogen decline more clearly explains where fat is stored (shifting toward the abdomen) than how much total weight is gained.
– Muscle loss reduces resting energy expenditure, meaning the same habits that once maintained your weight may need genuine recalibration. Not more willpower.
– Insulin sensitivity changes can make weight management feel more effortful even without a change in diet, independent of any personal failing.
– Your metabolism is not “broken.” This is a real, physiologically explainable transition, and understanding the mechanism can help you address it more effectively.
– Several of these contributors, especially muscle mass, sleep, activity, and nutrition patterns, are genuinely modifiable, even though the underlying hormonal transition itself is not something to fight against.
Myth vs. fact
| Myth | Fact |
|---|---|
| Menopause weight gain is all hormonal | Total weight gain is more closely related to aging. Menopause independently drives fat redistribution toward the abdomen and accelerated muscle loss |
| Your metabolism is broken | Metabolic changes are real but explainable. Reduced resting energy expenditure from muscle loss and hormonal shifts are physiological, not a malfunction |
| You just need more willpower | Insulin sensitivity shifts, appetite hormone changes from poor sleep, and reduced resting energy expenditure are physiological. This is not a discipline problem |
| Diet and exercise alone will fix it | Lifestyle is important but may not be sufficient on its own. A personalized approach that addresses the specific combination of factors is more effective |
| Hormone therapy causes weight gain | A Cochrane review found no evidence that HRT causes extra weight gain beyond what normally occurs at menopause. Some evidence suggests it may limit abdominal fat redistribution |
| Weight gain during menopause is inevitable | While body composition changes are common, the degree and impact vary significantly. Many contributing factors are modifiable |
—
What can help?
Because menopause weight gain is multifactorial, the most effective approach addresses multiple contributors rather than relying on any single intervention.
Prioritizing resistance training
Because muscle loss is a significant, modifiable contributor to reduced resting energy expenditure, resistance training directly addresses one of the more impactful factors discussed above.
A large meta-analysis of 101 studies involving nearly 5,700 postmenopausal women found that exercise training effectively increased muscle mass and fat-free mass, and decreased fat mass, body fat percentage, waist circumference, and visceral fat. Resistance training was most effective for muscle gain, while combined aerobic and resistance training showed the greatest overall body composition improvements.
A 2026 meta-analysis of 126 studies confirmed that resistance training significantly improved muscular strength and body composition in both premenopausal and postmenopausal women, with no significant difference between groups. In other words, it is never too late to benefit.
Adequate protein intake
Supporting muscle maintenance through adequate protein works synergistically with resistance training to address the muscle-related contributor specifically.
A randomized controlled trial in postmenopausal women found that resistance training significantly increased skeletal muscle mass (by approximately 1.2-1.4 kg over 12 weeks), though adding a high-protein diet did not show a clear additive effect on body composition beyond training alone in this particular study.
Still, adequate protein distributed across meals supports the anabolic response to exercise, which may be blunted in postmenopausal women.
Prioritizing sleep
Since sleep disruption independently affects appetite-regulating hormones, addressing sleep directly may reduce one of the more overlooked contributors to weight changes during this transition.
When sleep disruption is driven by night sweats or hot flashes, treating the underlying vasomotor symptoms (through hormone therapy or other evidence-based options) may improve sleep quality and, by extension, the metabolic consequences of poor sleep.
Individualized nutrition
Rather than assuming a generic diet approach, nutrition strategies that account for insulin sensitivity changes, adequate protein, and sustainable habits tend to be more effective than restrictive approaches, which can further reduce muscle mass if not carefully managed.
Stress management
Addressing chronic stress may help reduce cortisol-related abdominal fat storage, complementing the other strategies discussed here.
Medical evaluation when appropriate
Ruling out or addressing medical contributors, including thyroid dysfunction or medication effects, ensures other explanations are not being overlooked.
Hormone therapy and body composition
Research suggests that menopausal hormone therapy may have a favorable influence on body fat distribution, potentially limiting the shift toward abdominal and visceral fat. The PEPI trial found that women on estrogen-based regimens averaged 1 kg less weight gain and 1.2 cm less increase in waist circumference than those given placebo after 3 years.
However, a Cochrane review concluded there is not enough evidence to recommend hormone therapy specifically as a treatment for weight management. Its primary role remains symptom management, with body composition effects as a potential secondary benefit.
Despite its favorable influence on body fat distribution, menopausal hormone therapy cannot be recommended as a treatment for central obesity in midlife women.
GLP-1 medications, as one possible tool
For some women, particularly those with significant metabolic risk factors, GLP-1 receptor agonist medications may be an appropriate option to discuss.
A systematic review and meta-analysis in JAMA Internal Medicine found that GLP-1 receptor agonists produced greater weight loss among women than men. A meta-analysis of 47 randomized controlled trials found a mean weight reduction of 4.57 kg, with the greatest benefit in patients who were younger, female, and treated over a longer duration.
Importantly, recent evidence suggests GLP-1 receptor agonists provide weight loss primarily through selective fat mass reduction, with relative preservation of lean tissue. However, combining these medications with resistance training and adequate protein intake is important to protect muscle mass during any weight loss.
If you would like a personalized plan that addresses your specific combination of factors, schedule a consultation at Her Vital Wellness.
—
When should someone seek evaluation?
It is worth pursuing a personalized evaluation when:
- You want to understand which specific factors are most relevant to your own weight and body composition changes
- Weight changes are significant, rapid, or accompanied by other symptoms that suggest a medical cause worth ruling out
- You have tried general lifestyle approaches without meaningful change and want a more individualized strategy
- You are interested in strength training, nutrition planning, or GLP-1 medications and want guidance on how they fit together
- You want a plan that considers your muscle health, metabolic markers, and overall goals together, rather than addressing weight in isolation
What to bring to your appointment
- A brief timeline of when weight or body composition changes started
- Your current exercise routine (type, frequency, and intensity)
- A general sense of your eating patterns, especially protein intake
- Any medications you are currently taking
- Sleep quality and any changes
- Stress levels and how they have changed
- Family history of diabetes, thyroid disease, or cardiovascular disease
- Any previous lab work
- Questions you want answered
—
Looking at the whole picture
Weight and body composition changes during menopause are real and multifactorial. They are driven by the genuine interaction of estrogen-related fat redistribution, muscle loss, shifting insulin sensitivity, sleep, stress, and lifestyle factors. No single explanation tells the whole story, and no single intervention addresses every contributor.
A personalized plan considers your specific combination of factors and builds an approach around all of them together.
Your body is not working against you, and this is not a reflection of anything you have done wrong.
If you would like a personalized plan that addresses your specific contributors, book a weight management consultation.
—
Frequently asked questions about menopause weight gain
Is menopause weight gain actually caused by hormones?
Partially. Research suggests that total weight gain during midlife is more closely related to aging than to menopause specifically. However, the menopausal transition independently drives fat redistribution toward the abdomen and accelerated loss of lean muscle mass. So hormones play a significant role in body composition changes, even if total weight gain is multifactorial.
Why is my belly getting bigger even though I have not changed anything?
Estrogen decline shifts where your body preferentially stores fat, moving it from the hips and thighs toward the abdomen. At the same time, declining muscle mass reduces how many calories your body burns at rest. These two changes together can increase abdominal fat even without any change in your eating or activity habits.
Does menopause slow down your metabolism?
Not exactly. The concept of a “broken metabolism” is not accurate. What does happen is a decline in resting energy expenditure, largely driven by loss of muscle mass, along with reduced fat oxidation rates. These are real, measurable changes, but they are physiological responses to hormonal and aging-related shifts, not a malfunction.
Can you prevent weight gain during menopause?
While some degree of body composition change is common, the extent and impact vary significantly. Resistance training, adequate protein intake, quality sleep, stress management, and individualized nutrition can all help mitigate these changes. The most effective approach addresses multiple contributing factors rather than relying on any single strategy.
Does hormone therapy cause weight gain?
A Cochrane review found no evidence that hormone therapy causes extra weight gain beyond what normally occurs at menopause. Some research suggests it may actually help limit the shift toward abdominal fat distribution. However, it is not recommended specifically as a weight management treatment.
Why does weight loss feel so much harder after 40?
Several physiological changes converge: reduced resting energy expenditure from muscle loss, potential shifts in insulin sensitivity, changes in appetite-regulating hormones from disrupted sleep, and cortisol-related effects from chronic stress. These are not willpower issues. They are genuine metabolic shifts that may require a different approach than what worked in your 20s and 30s.
Is belly fat during menopause dangerous?
Visceral fat (fat stored deep in the abdomen around organs) is more metabolically active than subcutaneous fat. It is associated with increased risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome. This is one reason why the shift in fat distribution during menopause matters clinically, even when total weight has not changed dramatically.
Does resistance training really help with menopause weight gain?
Yes. A meta-analysis of 101 studies found that exercise training effectively increased muscle mass and decreased fat mass, body fat percentage, waist circumference, and visceral fat in postmenopausal women. Resistance training specifically was most effective for muscle gain, which directly addresses the reduced resting energy expenditure that contributes to weight gain.
Can GLP-1 medications help with menopause weight gain?
GLP-1 receptor agonists have shown significant efficacy for weight loss, with evidence suggesting greater benefit in women than men. Recent research indicates they may reduce fat mass while relatively preserving lean tissue. However, they work best combined with resistance training and adequate protein to protect muscle mass, and they are one tool among several, not a stand-alone solution.
Should I see a provider about menopause weight gain?
Consider seeking evaluation if weight changes are significant or rapid, if you have tried general approaches without results, if you want to understand which specific factors are driving your changes, or if you want a personalized plan that considers your metabolic health, muscle mass, and overall goals together. A thorough evaluation can also rule out other contributors like thyroid dysfunction.
Is it true that the same diet that worked in my 30s will not work now?
For many women, yes. Reduced resting energy expenditure from muscle loss, potential insulin sensitivity changes, and shifts in appetite-regulating hormones mean that the same caloric intake and activity level may no longer produce the same results. This is not a failure of the approach. It is a reflection of changed physiology that may benefit from recalibration, particularly around protein intake and resistance training.
Does stress really contribute to belly fat?
Research links chronic stress and elevated cortisol to increased visceral fat accumulation specifically. Cortisol promotes fat storage in abdominal depots and can compound the redistribution pattern already driven by estrogen decline. Addressing chronic stress is a genuinely meaningful part of a comprehensive approach.
(Telehealth appointments are currently available for patients located in Arizona and New York.)
This information is educational and not a substitute for personalized medical care.
References
- Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management. Kapoor E, Collazo-Clavell ML, Faubion SS. Mayo Clinic Proceedings. 2017;92(10):1552-1558. doi:10.1016/j.mayocp.2017.08.004.
- Body Weight and Fat Mass Across the Menopausal Transition: Hormonal Modulators. Moccia P, Belda-Montesinos R, Monllor-Tormos A, Chedraui P, Cano A. Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology. 2022;38(2):99-104. doi:10.1080/09513590.2021.2004395.
- Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. El Khoudary SR, Aggarwal B, Beckie TM, et al. Circulation. 2020;142(25):e506-e532. doi:10.1161/CIR.0000000000000912.
- Menopause: A Cardiometabolic Transition. Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T. The Lancet. Diabetes & Endocrinology. 2022;10(6):442-456. doi:10.1016/S2213-8587(22)00076-6.
- Fat Mass Changes During Menopause: A Metaanalysis. Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. American Journal of Obstetrics and Gynecology. 2019;221(5):393-409.e50. doi:10.1016/j.ajog.2019.04.023.
- Endocrinology of menopause. Edwards BJ, Li J. Periodontology 2000. 2013;61(1):177-94. doi:10.1111/j.1600-0757.2011.00407.x.
- Menopause, Female Sex Hormones, Skeletal Muscle Mass and Muscle Protein Turnover in Humans. Menzies C, Bowtell R, Shur N, Brook MS. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(1):e70232. doi:10.1002/jcsm.70232.
- Appendicular Lean Mass Is Lower in Late Compared With Early Perimenopausal Women: Potential Role of FSH. Park YM, Jankowski CM, Ozemek C, et al. Journal of Applied Physiology (Bethesda, Md. : 1985). 2020;128(5):1373-1380. doi:10.1152/japplphysiol.00315.2019.
- A Narrative Review of Energy Expenditure and Substrate Oxidation During Menopause. Marcantei C, Metz L, O’Donnell E, Isacco L. Climacteric : The Journal of the International Menopause Society. 2026;29(2):140-150. doi:10.1080/13697137.2025.2610485.
- Ectopic Lipid Deposition Is Associated With Insulin Resistance in Postmenopausal Women. Abildgaard J, Danielsen ER, Dorph E, et al. The Journal of Clinical Endocrinology and Metabolism. 2018;103(9):3394-3404. doi:10.1210/jc.2018-00554.
- Clinical Management of Obesity – Third Edition. Caroline M. Apovian MD, Louis Aronne MD, Sarah R. Barenbaum MD. The Obesity Society (2025).
- Effects of Acute Sleep Loss on Leptin, Ghrelin, and Adiponectin in Adults With Healthy Weight and Obesity: A Laboratory Study. van Egmond LT, Meth EMS, Engström J, et al. Obesity (Silver Spring, Md.). 2023;31(3):635-641. doi:10.1002/oby.23616.
- Associations of Short Sleep Duration With Appetite-Regulating Hormones and Adipokines: A Systematic Review and Meta-Analysis. Lin J, Jiang Y, Wang G, et al. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity. 2020;21(11):e13051. doi:10.1111/obr.13051.
- Elevated Ghrelin Predicts Food Intake During Experimental Sleep Restriction. Broussard JL, Kilkus JM, Delebecque F, et al. Obesity (Silver Spring, Md.). 2016;24(1):132-8. doi:10.1002/oby.21321.
- Effects of Experimental Sleep Restriction on Energy Intake, Energy Expenditure, And Visceral Obesity. Covassin N, Singh P, McCrady-Spitzer SK, et al. Journal of the American College of Cardiology. 2022;79(13):1254-1265. doi:10.1016/j.jacc.2022.01.038.
- Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association. St-Onge MP, Grandner MA, Brown D, et al. Circulation. 2016;134(18):e367-e386. doi:10.1161/CIR.0000000000000444.
- Clinical Review: The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. The Journal of Clinical Endocrinology and Metabolism. 2009;94(8):2692-701. doi:10.1210/jc.2009-0370.
- The Hypothalamic-Pituitary-Adrenal Axis and Sex Hormones in Chronic Stress and Obesity: Pathophysiological and Clinical Aspects. Pasquali R. Annals of the New York Academy of Sciences. 2012;1264:20-35. doi:10.1111/j.1749-6632.2012.06569.x.
- Stress, Visceral Obesity, and Metabolic Complications. Kyrou I, Chrousos GP, Tsigos C. Annals of the New York Academy of Sciences. 2006;1083:77-110. doi:10.1196/annals.1367.008.
- Cardiovascular Health in Women—Across the Lifespan. Chandrasekhar J, Yao J, Gong S, et al. Clinical Endocrinology. 2026;104(6):539-555. doi:10.1111/cen.70027.
- Analysis of Combinatory Effects of Free Weight Resistance Training and a High-Protein Diet on Body Composition and Strength Capacity in Postmenopausal Women – A 12-Week Randomized Controlled Trial. Ioannidou P, Dóró Z, Schalla J, et al. The Journal of Nutrition, Health & Aging. 2024;28(10):100349. doi:10.1016/j.jnha.2024.100349.
- Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort. Papadakis GE, Hans D, Gonzalez Rodriguez E, et al. The Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1948-1957. doi:10.1210/jc.2017-02449.
- Oestrogen and Progestogen Hormone Replacement Therapy for Peri-Menopausal and Post-Menopausal Women: Weight and Body Fat Distribution. Norman RJ, Flight IH, Rees MC. The Cochrane Database of Systematic Reviews. 2000;(2):CD001018. doi:10.1002/14651858.CD001018.
- The Effects of Exercise Training on Body Composition in Postmenopausal Women: A Systematic Review and Meta-Analysis. Khalafi M, Habibi Maleki A, Sakhaei MH, et al. Frontiers in Endocrinology. 2023;14:1183765. doi:10.3389/fendo.2023.1183765.
- It’s Never Too Late: The Impact of Resistance Training on Strength and Body Composition in Females Across the Lifespan – A Systematic Review and Meta-Analysis. Isenmann E, Geisler S, Havers T, et al. Journal of Science and Medicine in Sport. 2026;:S1440-2440(26)00096-4. doi:10.1016/j.jsams.2026.03.002.
- Adipose Tissue Sex Steroids in Postmenopausal Women With and Without Menopausal Hormone Therapy. Hetemäki N, Robciuc A, Vihma V, et al. The Journal of Clinical Endocrinology and Metabolism. 2025;110(2):511-522. doi:10.1210/clinem/dgae458.
- Effect of Postmenopausal Hormone Therapy on Body Weight and Waist and Hip Girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. The Journal of Clinical Endocrinology and Metabolism. 1997;82(5):1549-56. doi:10.1210/jcem.82.5.3925.
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults. Alexander GC, Xiao X, Dilek S, et al. JAMA Internal Medicine. 2026;:2845663. doi:10.1001/jamainternmed.2025.8222.
- Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-Analysis, and Meta-Regression of 47 Randomized Controlled Trials. Wong HJ, Sim B, Teo YH, et al. Diabetes Care. 2025;48(2):292-300. doi:10.2337/dc24-1678.
- GLP-1 Agonists and Changes in Body Mass and Composition in Adults With Overweight or Obesity With or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Sawicka-Gutaj N, Gruszczyński D, Nijakowski K, et al. International Journal of Obesity (2005). 2026;:10.1038/s41366-026-02088-1. doi:10.1038/s41366-026-02088-1.
- Adipose-Muscle Crosstalk During the Menopausal Transition: Mechanistic Links to Sarcopenic Obesity in Midlife Women. Zhang W, Wu Q, Chen Q, et al. Frontiers in Endocrinology. 2026;17:1805067. doi:10.3389/fendo.2026.1805067.
- Short sleep duration and obesity: mechanisms and future perspectives. Zimberg IZ, Dâmaso A, Del Re M, et al. Cell Biochemistry and Function. 2012;30(6):524-9. doi:10.1002/cbf.2832.
- Metabolic and hormonal effects of ‘catch‐up’ sleep in men with chronic, repetitive, lifestyle‐driven sleep restriction. Killick R, Hoyos CM, Melehan KL, et al. Clinical Endocrinology. 2015;83(4):498-507. doi:10.1111/cen.12747.
- GLP‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs. Vienghirun J, Sawangjit R, Suttiruksa S, et al. Diabetes, Obesity & Metabolism. 2026;28(6):5043-5057. doi:10.1111/dom.70698.